AstraZeneca says Imfinzi plus tarlatamab cut death risk 58% in lung cancer trial
AstraZeneca reported Phase III data showing Imfinzi with tarlatamab reduced the risk of death by 58% versus Imfinzi alone in first-line maintenance treatment.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
AstraZeneca said that combining Imfinzi (durvalumab) with Amgen's tarlatamab-dlle lowered the risk of death by 58% compared with Imfinzi alone as first-line maintenance therapy for extensive-stage small cell lung cancer. The overall survival hazard ratio was 0.42, with p<0.001. Median overall survival reached 21.1 months, versus 12.7 months in the comparison group.
According to the company, the risk of progression or death fell by 66% (PFS HR 0.34, p<0.001). Median progression-free survival was 7.4 months against 1.9 months, and the objective response rate rose to 26.4% from 4.1%. AstraZeneca noted that the safety profile was consistent with expectations and that no treatment-related deaths were recorded.
The information is based on material from TradingView, which cites AstraZeneca's press release distributed via BusinessWire.
why it matters
For AstraZeneca and Amgen, this is confirmation of late-stage trial data. A larger business effect would depend on regulatory filings, approvals, updates to clinical guidelines and clarity on commercial terms between the two companies.
market impact
AZN and AMGN: strong trial data supports the drugs' position in oncology and could expand Imfinzi sales.
tags
instruments
sources
- AstraZeneca (AZN) Says Durvalumab+Tarlatamab Cut Death Risk 58% in ES-SCLC Phase III — TradingView, 24 October 2026 at 14:35 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗